PET scan imaging study for solid tumors using a new probe
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Cancer, Digestive system, Ear, nose & throat, Eyes & vision, Genetic & congenital, Heart & circulation, Hormones & metabolism, Immune system & allergy, Infections, Injuries & trauma, Kidney & urinary, Lungs & breathing, Mental health, Mouth & dental, Pain, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new imaging agent that targets a protein called B7-H3 found on many solid tumors. It uses PET/CT to help doctors see and stage tumors more clearly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your blood counts, liver, and kidney function need to be within certain ranges (your doctor can check this).
- You must have at least one measurable tumor that can be seen on a scan.
- You should be able to lie still for about 30 minutes.
- If you are able to become pregnant or are sexually active, you must use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This trial tests a new type of PET scan (a special imaging test) called 89Zr-s-C1 to help detect and monitor solid tumors like melanoma, gastric cancer, or colorectal cancer. The scan may help doctors see tumors more clearly and track whether treatment is working.
This trial evaluates a new radioactive tracer that targets a protein called EpCAM found on many solid tumors. It aims to improve PET/CT scans for diagnosing and staging cancer. Participants will receive the tracer before their scheduled biopsy or surgery.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
Hear when a new B7H3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.